[go: up one dir, main page]

AR029557A1 - Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis - Google Patents

Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis

Info

Publication number
AR029557A1
AR029557A1 ARP010103174A ARP010103174A AR029557A1 AR 029557 A1 AR029557 A1 AR 029557A1 AR P010103174 A ARP010103174 A AR P010103174A AR P010103174 A ARP010103174 A AR P010103174A AR 029557 A1 AR029557 A1 AR 029557A1
Authority
AR
Argentina
Prior art keywords
mastitis
prevention
treatment
composition
oxazolidinone
Prior art date
Application number
ARP010103174A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR029557A1 publication Critical patent/AR029557A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente se relaciona con una composicion para el tratamiento o prevencion de la mastitis en mamíferos por medio de agentes antibacterianos de oxazolidinonas conocidas, solos o en combinacion con lactoferrinas exogenas.
ARP010103174A 2000-07-05 2001-07-03 Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis AR029557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21590000P 2000-07-05 2000-07-05

Publications (1)

Publication Number Publication Date
AR029557A1 true AR029557A1 (es) 2003-07-02

Family

ID=22804869

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103174A AR029557A1 (es) 2000-07-05 2001-07-03 Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis

Country Status (9)

Country Link
US (1) US6562820B2 (es)
EP (1) EP1299106A2 (es)
JP (1) JP2004501973A (es)
AR (1) AR029557A1 (es)
AU (2) AU6970101A (es)
CA (1) CA2410476A1 (es)
NZ (1) NZ523448A (es)
PE (1) PE20020236A1 (es)
WO (1) WO2002002121A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3597491B2 (ja) * 2001-06-27 2004-12-08 株式会社ティーセル研究所 泌乳牛における乳腺の免疫賦活化剤および賦活化方法
EP2138171A1 (en) * 2008-06-18 2009-12-30 Istituto Superiore Di Sanita' Veterinarian compositions containing terpinen-4-ol for the treatment and prevention of mastitis
BRPI0923252A2 (pt) * 2008-12-04 2016-11-01 Merial Ltd vedador de bico de seio intramamário
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
RU2547550C1 (ru) * 2013-12-26 2015-04-10 Государственное научное учреждение Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии Российской академии сельскохозяйственных наук (ГНУ ВНИВИПФиТ Россельхозакадемии) Способ лечения мастита у лактирующих овец
AU2016250668B2 (en) 2015-04-24 2020-07-02 Sanuwave, Inc. Tissue disinfection with acoustic pressure shock waves
JP2018127399A (ja) * 2015-06-17 2018-08-16 共立製薬株式会社 牛の泌乳期の甚急性又は急性乳房炎に対する治療剤、並びに治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
NZ501412A (en) 1997-05-30 2001-11-30 Upjohn Co Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6040306A (en) 1997-11-18 2000-03-21 Pharmacia & Upjohn Company Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
EP1049682A1 (en) 1998-01-23 2000-11-08 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
MY122454A (en) 1998-06-05 2006-04-29 Upjohn Co Use of oxazolidinones for the preparation of a medicament for transdermal delivery
EE200100026A (et) 1998-07-14 2002-06-17 Pharmacia & Upjohn Company Oksasolidinoonid silmahaiguste raviks

Also Published As

Publication number Publication date
EP1299106A2 (en) 2003-04-09
JP2004501973A (ja) 2004-01-22
AU6970101A (en) 2002-01-14
US6562820B2 (en) 2003-05-13
US20020111349A1 (en) 2002-08-15
WO2002002121A2 (en) 2002-01-10
PE20020236A1 (es) 2002-03-13
WO2002002121A3 (en) 2002-05-02
NZ523448A (en) 2004-12-24
AU2001269701B2 (en) 2005-10-27
CA2410476A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MY144318A (en) Methods of treating hiv infection.
AR109263A2 (es) Composición que comprende moxidectina
BRPI0411770A (pt) dispositivo aperfeiçoado de distribuição
AR016504A1 (es) Composicion proteica estabilizada, forma farmaceutica de dosificacion, un metodo para preparar una forma farmaceutica de dosificacion, uso de la composicion proteica en la fabricacion de medicamentos y kit
EA200800950A1 (ru) Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо
AR028041A1 (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
AR029557A1 (es) Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis
UY30629A1 (es) Nuevo péptido de actinomadura namibiensis
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
SE0004101D0 (sv) New use
CL2008002223A1 (es) Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria.
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
BR0210632A (pt) Tratamento de doença parasìtica
SE0000303D0 (sv) Novel compounds
BR0010499A (pt) Agentes endoparasiticidas
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
GB0400774D0 (en) Pharmaceutical composition
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12

Legal Events

Date Code Title Description
FB Suspension of granting procedure